Oruka Therapeutics
ORKA
79.50
-0.68
-0.85%
Oruka Therapeutics
US · ORKA
#2003 by market cap
Listed 1970
79.50
-0.68
-0.85%
Live - 5344 symbols - heartbeat 505s ago
· 2026-10-08 06:50
Pre-market
78.50
-1.26%
After-hours
79.50
0.00%
- Market cap
- 5.26B
- P/E (TTM)i
- -38.97
- P/Bi
- 4.74
- EPSi
- -1.85
- Div yieldi
- 0.00%
- 52W posi
- 60%
Reader sentiment
Are you bullish or bearish on ORKA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 9.6 percentage points.
Institutional ownership
- Held by institutions
- 113.10% -9.62pp
- Institutions
- 306 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund68.12%
Hedge Fund26.64%
VC/PE Fund14.26%
Individual/Insider2.21%
Private Company1.83%
Public Company1.43%
Sovereign Wealth Fund0.39%
Government Pension Fund0.20%
Insurance Company0.15%
Top holders as of 2026-06-30
FMR
13.68% · 9.06M sh
BlackRock
7.54% · 4.99M sh
VR Management, LLC
6.27% · 4.15M sh
Fairmount Funds Management LLC
5.60% · 3.71M sh
Capital Research
5.14% · 3.40M sh
RTW Investments, LP
4.74% · 3.14M sh
Vanguard Capital Management, LLC
4.12% · 2.73M sh
State Street Global Advisors
4.04% · 2.67M sh
Paradigm Biocapital Advisors LP
3.24% · 2.14M sh
T. Rowe Price Group, Inc.
2.93% · 1.94M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 7 buys · 43 sells
| Name | Role | Stake |
|---|---|---|
| Lawrence Klein | Chief Executive Officer | 1.39% |
| Laura Sandler | Senior Vice President of Operations & Boston Site Head | 0.36% |
| Larry Edwards | Chief Commercial Officer | 0.15% |
| Cameron Turtle | Independent Director | 0.13% |
| Carl Dambkowski | Independent Director | 0.06% |
| Joana Goncalves | Chief Medical Officer | 0.05% |
| Paul Quinlan | General Counsel | 0.05% |
| Arjun Agarwal | Senior Vice President of Finance & Treasurer | 0.02% |
| Bong Koh | -- | -- |
| Kristine Ball | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Lawrence Klein | Chief Executive Officer | Derivative Exercise and Sale | -25,000 | $7.80–84.78 |
| 2026-09-20 | Paul Quinlan | General Counsel | Derivative Exercise and Sale | -10,000 | $7.80–95.31 |
| 2026-09-20 | Arjun Agarwal | Senior Vice President of Finance & Treasurer | Automatic Disposition | -533 | $95.75 |
| 2026-09-14 | Paul Quinlan | General Counsel | Open Market Disposition | -1,039 | $95.71 |
| 2026-09-14 | Joana Goncalves | Chief Medical Officer | Open Market Disposition | -947 | $95.71 |
| 2026-09-14 | Joana Goncalves | Chief Medical Officer | Derivative Exercise and Sale | -7,000 | $6.84–94.22 |
| 2026-09-14 | Lawrence Klein | Chief Executive Officer | Open Market Disposition | -2,452 | $95.71 |
| 2026-09-14 | Arjun Agarwal | Senior Vice President of Finance & Treasurer | Open Market Disposition | -560 | $95.71 |
| 2026-09-14 | Laura Sandler | Senior Vice President of Operations & Boston Site Head | Open Market Disposition | -906 | $95.71 |
| 2026-09-10 | Arjun Agarwal | Senior Vice President of Finance & Treasurer | Derivative Exercise and Sale | -9,459 | $12.50–94.02 |
| 2026-08-31 | Lawrence Klein | Chief Executive Officer | Derivative Exercise and Sale | -75,000 | $7.80–92.44 |
| 2026-08-31 | Laura Sandler | Senior Vice President of Operations & Boston Site Head | Derivative Exercise and Sale | -5,000 | $7.80–92.01 |
| 2026-08-23 | Larry Edwards | Chief Commercial Officer | Other Acquisition | +100,000 | -- |
| 2026-08-23 | Larry Edwards | Chief Commercial Officer | Other Derivative Acquisition | +20,000 | $102.42 |
| 2026-08-16 | Joana Goncalves | Chief Medical Officer | Derivative Exercise and Sale | -7,000 | $6.84–112.56 |
| 2026-08-13 | Paul Quinlan | General Counsel | Derivative Exercise and Sale | -52,000 | $7.80–111.14 |
| 2026-08-12 | Arjun Agarwal | Senior Vice President of Finance & Treasurer | Derivative Exercise and Sale | -10,000 | $12.50–108.46 |
| 2026-07-14 | Joana Goncalves | Chief Medical Officer | Derivative Exercise and Sale | -7,000 | $6.84–87.25 |
| 2026-07-12 | Arjun Agarwal | Senior Vice President of Finance & Treasurer | Derivative Exercise and Sale | -9,999 | $12.50–85.63 |
| 2026-06-30 | Fairmount Funds Management LLC | -- | Intent to Sell (Form 144) | -3,553,410 | $84.43 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:50:07 · For reference only, not investment advice and not tailored to your situation.